🚀 VC round data is live in beta, check it out!
Nyrada Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nyrada and similar public comparables like Starpharma, Alpha Cognition, Macrogenics, Captor Therapeutics and more.
Nyrada Overview
About Nyrada
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. It operates in one segment: research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical needs. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
Founded
2019
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$123M
Nyrada Stock Performance
Nyrada has current market cap of $125M, and enterprise value of $123M.
Market Cap Evolution
Nyrada's stock price is $0.51.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $123M | $125M | — | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNyrada Valuation Multiples
Nyrada Financial Valuation Multiples
As of March 29, 2026, Nyrada has market cap of $125M and EV of $123M.
Equity research analysts estimate Nyrada's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $125M | XXX | $125M | XXX | XXX | XXX |
| EV (current) | $123M | XXX | $123M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nyrada Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Nyrada Margins & Growth Rates
Nyrada's revenue in the last fiscal year grew by —.
Nyrada Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 21% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Nyrada Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Alpha Cognition | XXX | XXX | XXX | XXX | XXX | XXX |
| Macrogenics | XXX | XXX | XXX | XXX | XXX | XXX |
| Captor Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tenaya Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nyrada M&A Activity
Nyrada acquired XXX companies to date.
Last acquisition by Nyrada was on XXXXXXXX, XXXXX. Nyrada acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Nyrada
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNyrada Investment Activity
Nyrada invested in XXX companies to date.
Nyrada made its latest investment on XXXXXXXX, XXXXX. Nyrada invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Nyrada
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nyrada
| When was Nyrada founded? | Nyrada was founded in 2019. |
| Where is Nyrada headquartered? | Nyrada is headquartered in Australia. |
| Is Nyrada publicly listed? | Yes, Nyrada is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Nyrada? | Nyrada trades under NYR ticker. |
| When did Nyrada go public? | Nyrada went public in 2020. |
| Who are competitors of Nyrada? | Nyrada main competitors are Starpharma, Alpha Cognition, Macrogenics, Captor Therapeutics. |
| What is the current market cap of Nyrada? | Nyrada's current market cap is $125M. |
| Is Nyrada profitable? | No, Nyrada is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.